AVEIR VR Real-World Evidence Study
ABBOTT MEDICAL · Decision date Oct 21, 2026
What did the FDA approve?
The FDA record shows an approval dated 2026-10-21 for a revised protocol governing the post-approval study (PAS) tied to P150035/S042. The supplement is filed under the Normal 180 Day Track No User Fee pathway, with the stated reason "Postapproval Study Protocol." The changed item is the PAS protocol itself, not the underlying PMA for the leadless pacemaker (product code PNJ, cardiovascular specialty, applicant Abbott Medical).
The supplied statement says the protocol was submitted to comply with conditions of approval in the earlier approval order for P150035/S041, which is the only stated link to the original PMA. That describes a filing purpose, not independent evidence of safety or clinical effectiveness. Details absent from the source include study endpoints, sample size, follow-up duration and the specific conditions being addressed, so the protocol's substantive requirements cannot be described here.
FDA approval order statement
approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P150035/S041.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 21, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150035/S042
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- PNJ
- Decision code
- APPR
- Decision date
- Oct 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Leadless pacemaker.
- Applicant
- Abbott Medical
- Product code
- PNJ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150035. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150035 · Original PMA
Aveir VR Leadless System
P150035/S042 received
Application receipt date recorded by FDA.
P150035/S042 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P150035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Aveir VR Leadless SystemP150035 | ABBOTT MEDICAL | PMA approval | Mar 31, 2022 | FDA |
Explore the linked device profile
Other records with product code PNJ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Micra Functional Testing on pNGHT and NGHTP150033/S230 | Medtronic, Inc. | PMA supplement | Sep 8, 2026 | FDA |
| Medtronic, Inc. | PMA approval | Apr 6, 2016 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 15900 Valley View Ct., Sylmar, CA, 91342
Sources and methodology
- Original FDA record: P150035/S042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

